|
CAK-ERCC2 complex
|
GO_0070516 |
[A protein complex formed by the association of the cyclin-dependent protein kinase activating kinase (CAK) holoenzyme complex with ERCC2.] |
|
DNA replication factor C core complex
|
GO_0070517 |
[A protein complex containing three of the five subunits of eukaryotic replication factor C, those corresponding to human p40, p38, and p37.] |
|
alpha4-beta1 integrin-CD53 complex
|
GO_0070518 |
[A protein complex that consists of an alpha4-beta1 integrin complex bound to membrane protein CD53, a member of the tetraspan family.] |
|
alpha4-beta1 integrin-CD63 complex
|
GO_0070519 |
[A protein complex that consists of an alpha4-beta1 integrin complex bound to membrane protein CD63, a member of the tetraspan family.] |
|
negative regulation of T cell activation
|
GO_0050868 |
[Any process that stops, prevents, or reduces the frequency, rate or extent of T cell activation.] |
|
positive regulation of imaginal disc growth
|
GO_0045572 |
[Any process that activates or increases the frequency, rate or extent of imaginal disc growth.] |
|
regulation of imaginal disc growth
|
GO_0045570 |
[Any process that modulates the frequency, rate or extent of the growth of the imaginal disc.] |
|
GO_0045573
|
GO_0045573 |
|
|
sterigmatocystin catabolic process
|
GO_0045574 |
[The chemical reactions and pathways resulting in the breakdown of sterigmatocystin, a carcinogenic mycotoxin produced in high yields by strains of the common molds.] |
|
sterigmatocystin metabolic process
|
GO_0045460 |
[The chemical reactions and pathways involving sterigmatocystin, a carcinogenic mycotoxin produced in high yields by strains of the common molds.] |
|
basophil activation
|
GO_0045575 |
[The change in morphology and behavior of a basophil resulting from exposure to a cytokine, chemokine, soluble factor, or to (at least in mammals) an antigen which the basophil has specifically bound via IgE bound to Fc-epsilonRI receptors.] |
|
granulocyte activation
|
GO_0036230 |
[The change in morphology and behavior of a granulocyte resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.] |
|
mast cell activation
|
GO_0045576 |
[The change in morphology and behavior of a mast cell resulting from exposure to a cytokine, chemokine, soluble factor, or to (at least in mammals) an antigen which the mast cell has specifically bound via IgE bound to Fc-epsilonRI receptors.] |
|
myeloid leukocyte activation
|
GO_0002274 |
[A change in the morphology or behavior of a myeloid leukocyte resulting from exposure to an activating factor such as a cellular or soluble ligand.] |
|
obsolete poly-gamma-glutamate metabolic process
|
GO_0070500 |
[OBSOLETE. The chemical reactions and pathways involving poly-gamma-glutamate, a polymer of D- and/or L-glutamic acid residues linked by gamma-peptidyl bonds.] |
|
regulation of B cell differentiation
|
GO_0045577 |
[Any process that modulates the frequency, rate or extent of B cell differentiation.] |
|
regulation of B cell activation
|
GO_0050864 |
[Any process that modulates the frequency, rate or extent of B cell activation.] |
|
poly-gamma-glutamate biosynthetic process
|
GO_0070501 |
[The chemical reactions and pathways resulting in the formation of poly-gamma-glutamate, a polymer of D- and/or L-glutamic acid residues linked by gamma-peptidyl bonds.] |
|
negative regulation of B cell differentiation
|
GO_0045578 |
[Any process that stops, prevents, or reduces the frequency, rate or extent of B cell differentiation.] |
|
capsule poly-gamma-glutamate biosynthetic process
|
GO_0070502 |
[The chemical reactions and pathways resulting in the formation of poly-gamma-glutamate, a polymer of D- and/or L-glutamic acid residues linked by gamma-peptidyl bonds, that forms all or part of a bacterial capsule.] |